PR Newswire (press release) DIFICID, a macrolide antibacterial drug, was approved by the U.S. Food and Drug Administration on May 27, 2011, for the treatment of Clostridium difficile-associated diarrhea, or CDAD, in adults 18 years of age and older. Fidaxomicin has also received ... and more »
Yahoo! New Zealand News The company also intends to use its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about ... and more »
Seeking Alpha Biocyclolides are a new class of macrolide antibiotics developed by Enanta that have been designed to overcome resistance more effectively than existing macrolide products such as Biaxin or Zithromax. IND-enabling studies are now in progress, and ...
DigitalJournal.com (press release) FDA is in the process of updating risk information in the drug labels for additional macrolide antibacterial drugs.” The New England Journal of Medicine study included research compiled from information accumulated from about 350,000 patients who were ...
Corante I am curious to see how it works with cyclic peptides and how it may branch out in to more ' macrolide -like' macrocycles. Permalink to Comment · 7. weirdo on July 25, 2013 4:44 PM writes... OK, OK, I'm not at this conference, so I don't know exactly was ...
MarketWatch (press release) About DIFICID� (fidaxomicin) Tablets DIFICID is the first macrolide antibacterial drug indicated for Clostridium difficile-associated diarr...
MarketWatch (press release) Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum ... and more »
